GlassScriptPhysician profile
Paul Charles Thomas
NPI 1427026749
$10,068.81
in general payments reported to CMS, 2019-2025
41 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $3,697 · 2021: $795 · 2022: $966 · 2023: $964 · 2024: $973 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,351.23 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Pfizer INC. | $1,313.95 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $843.14 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $809.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $659.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $494.84 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.21 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $289.95 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $201.22 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Janssen Pharmaceuticals, INC | $195.19 | 2019-2022 | |
| Abbott Laboratories | $182.90 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $167.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $96.64 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $92.23 | 2020-2021 | |
| Sanofi Pasteur INC. | $87.50 | 2020-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.